Trial Profile
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Pharmacokinetics of SNAC in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Ciclosporin; Probenecid
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 29 Jun 2021 Primary endpoint has been met (Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide) , according to Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Primary endpoint has been met (AUC0-tz,SNAC,SD, area under the SNAC plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide) , Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association